Currently, there are no good mouse models to study the development of non-alcoholic steatohepatitis (NASH) and its progression to steatolic hepatocellular carcinoma (HCC) in less than one year. While there are other models of NASH in mice, none of the currently available models closely mimics the human disease and most are models of toxic liver damage associated with weight loss rather than obesity.
The mouse model described here has been recently developed by researchers at UC San Diego. It mimics the pathology of human NASH and steatolic HCC. NASH appears within 24 weeks and HCC develops within 40 weeks. This model may be used to evaluate compounds, drugs, diet, devices, etc. that prevent or ameliorate NASH and attenuate its progression to HCC.
This model can potentially be very useful in studying NASH and HCC.
|United States Of America||Issued Patent||10,034,462||07/31/2018||2014-361|
non-alcoholic liver disease, non-alcoholic steatohepatitis, liver cancer, hepatocellular carcinoma